JAMA Neurology

08/08/2026

In , automated of a brief picture description task distinguished nonfluent, logopenic, and semantic variants and produced interpretable speech profiles.

https://ja.ma/3Ul5biI

08/08/2026

In , higher serum glial fibrillary acidic protein was associated with greater risk of progression independent of relapse activity, while neurofilament light chain was more closely associated with relapse risk.

https://ja.ma/4hmlPbu

08/03/2026

This cohort study examines data for a large population-based cohort to identify and characterize any cases of primary Epstein-Barr virus infection that occurred after the onset of multiple sclerosis. https://ja.ma/3SbXzhU

08/03/2026

This case report describes a 60-year-old woman presenting with sudden loss of muscle tone with preserved consciousness and severe daytime sleepiness.

https://ja.ma/4g79Opc

08/03/2026

In an autopsy-confirmed subset, automated profiles also aligned with the most common underlying neuropathological classes in .

Brief connected speech samples may help support clinical classification, biological characterization, and longitudinal monitoring in both care settings and trials.

https://ja.ma/4hgyixr

08/03/2026

Among patients with treated with fingolimod or B-cell–depleting therapy, reductions in serum glial fibrillary acidic protein during the first 2 years of treatment were associated with lower subsequent risk of progression independent of relapse activity.

These results suggest potential use of glial fibrillary acidic protein for personalized risk stratification, treatment monitoring, and clinical trial enrichment targeting progression.

https://ja.ma/4bpyqqu

08/03/2026

In a randomized clinical trial published in JAMA Neurology, first-line disease-modifying therapy was assessed in adults with stable who had been free of relapses and substantial activity for at least 5 years. Discontinuation was associated with recurrent inflammatory disease activity, while no primary outcome events occurred in the continuation group.

These findings indicate that stopping first-line disease-modifying therapy may not be safe for all patients with stable multiple sclerosis and may inform clinical decision-making about treatment continuation and monitoring.

JAMA Neurology Editor in Chief S. Andrew Josephson, MD, selected this as his 2025 Editor's Choice: Clinical Trial of the Year because it provides important evidence that discontinuing disease-modifying therapy in patients with stable multiple sclerosis may significantly increase the risk of relapse.

🔗 Read the Editorial: https://ja.ma/3RMmwQL
📖 Read the trial:
https://ja.ma/4fA9SgZ

📌 How can clinicians and researchers stay up to date on the most clinically relevant trials?

JAMA+ Trials highlights the implications and innovations of clinical trial research from across the JAMA Network to advance evidence-based medicine and public health. Follow JAMA+ Trials to get curated access to the best of the JAMA Network’s trial research, commentaries, and educational resources: https://ja.ma/3RMmyrR

08/03/2026

Patients with functional disorder exhibit frequent psychiatric and neurological comorbidities, worse functional outcomes, higher health care use, and increased mortality compared with multiple sclerosis.

https://ja.ma/4xhiZZY

07/29/2026

Interview with Kelly G. Gwathmey, MD, author of Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis: The PREVAIL Phase 3 Randomized Clinical Trial. Hosted by Cynthia E. Armand, MD.

Interview with Kelly G. Gwathmey, MD, author of Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis: The PREVAIL Phase 3 Randomized Clinical Trial. Hosted by Cynthia E. Armand, MD.

07/29/2026

💬 Editorial by Dixon Yang, MD, MS, Holly Elser, MD, PhD, and Allison Willis, MD, MS: Environmental exposures associated with include pesticides, hydrocarbon solvents, air pollutants, and residence near farms, industrial sites, or golf courses. National cohort data from Denmark add road traffic noise to this list, suggesting that long-term residential noise exposure may be another place-based risk factor relevant to Parkinson disease.

Parkinson disease (PD) affects over 11 million people worldwide and is among the fastest-growing causes of neurological death and disability.1 This trend highlights the critical need to identify and address modifiable risk factors of PD. Several environmental chemicals have been linked to PD risk,.....